Abstract
Introduction: Intratumor administration of short-term expression vectors encoding interleukin 12 (IL-12) can satisfactory eradicate liver neoplasm in animal models, although little efficacy was shown in pilot clinical trials. Therefore, long-term expression of IL-12 within the liver may be advantageous. Due to toxicity of IL-12, vectors should contain systems for efficient gene regulation. The Tet-on system is composed of a chimeric trans-activator (rtTA2S-M2) and a doxycycline (Dox)-dependent inducible promoter. In this work we pursued: a) the optimization of Tet-on system for tight and liver-specific IL-12 regulation, and b) its application for the treatment of hepatic tumors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
